About Likarda, llc
Likarda, LLC: Revolutionizing Cell Therapy with Customized Platforms
Likarda, LLC is a pioneering biotechnology company that has developed the first and only customized platform for targeting cell therapies to increase potency. The company's innovative approach to cell therapy has the potential to revolutionize the field of regenerative medicine by providing a more effective and personalized treatment option for patients.
Founded in 2009 by Dr. Karthik Ramachandran and Dr. Maciej J. Zborowski, Likarda is headquartered in Kansas City, Missouri. The company's mission is to develop cutting-edge technologies that enable the delivery of targeted cell therapies for various diseases and conditions.
Likarda's proprietary technology platform allows for the customization of cell therapies based on individual patient needs. This personalized approach ensures that each patient receives a treatment that is tailored specifically to their unique biology, increasing its effectiveness while minimizing side effects.
The Likarda team consists of experienced scientists and researchers who are dedicated to advancing the field of regenerative medicine through innovation and collaboration. Their expertise spans across multiple disciplines including stem cells, immunology, oncology, drug discovery, and more.
One of Likarda's most significant achievements was developing an insulin-producing micro-pancreas using stem cells from pigs. This breakthrough technology has enormous potential in treating diabetes as it can provide a long-term solution without requiring daily insulin injections or transplants from human donors.
Likarda also offers contract research services to pharmaceutical companies looking to develop new drugs or test existing ones on their customized platforms. Their state-of-the-art facilities are equipped with cutting-edge equipment such as flow cytometers, confocal microscopes, high-throughput screening systems among others which allow them to conduct complex experiments efficiently.
In addition to its groundbreaking research efforts in regenerative medicine and drug development services offered through its contract research organization (CRO), Likarda also provides educational resources on its website about various topics related to stem cells, cell therapy, and regenerative medicine.
Likarda's innovative approach to cell therapy has garnered recognition from various organizations. The company has received several awards, including the 2019 Kansas City Business Journal Innovation Award and the 2018 Pipeline Entrepreneurial Fellowship.
In conclusion, Likarda is a biotechnology company that is revolutionizing the field of regenerative medicine with its customized platform for targeting cell therapies. Its personalized approach to treatment ensures that each patient receives a tailored solution that maximizes effectiveness while minimizing side effects. With its experienced team of scientists and researchers, state-of-the-art facilities, and commitment to innovation, Likarda is poised to make significant contributions in advancing the field of regenerative medicine in the years ahead.